Press Release Details

Sep 23, 2019

Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer

 LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 23, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has named Jeffrey A. Munsie to the position of Chief Legal Officer. In this role, Mr. Munsie will have overall responsibility for key general corporate legal functions, including the Company’s public reporting requirements, governance and intellectual property matters, and will serve as corporate secretary. Mr. Munsie will join Concert’s Executive Leadership Team and report to Roger Tung, Ph.D., President and Chief Executive Officer.

“Jeff has a strong track record for building and managing legal teams and, additionally, his strategic and operational expertise will be a significant asset to Concert,” said Dr. Tung. “We are delighted to welcome Jeff to our team.”

Mr. Munsie joins Concert with more than 17 years of legal and operational experience, most recently serving as Senior Vice President, General Counsel and Head of Corporate Operations at Merrimack Pharmaceuticals. Prior to Merrimack, he was a member of the corporate department at the law firm Wilmer Cutler Pickering Hale and Dorr in Boston. Mr. Munsie received a J.D. from Harvard Law School and a B.A. from Dartmouth College.

“I am truly excited to join Concert as it continues to make clinical progress with its pipeline of innovative medicines for chronic diseases, and I look forward to working with the management team to support Concert’s product development strategies and next stages of business growth,” said Mr. Munsie.

 About Concert  

 Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

 Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc. 

Source: Concert Pharmaceuticals, Inc.

Justine E. Koenigsberg (Investors)
Concert Pharmaceuticals, Inc.
(781) 674-5284
ir@concertpharma.com 

Kathryn Morris (media)
The Yates Network
(914) 204-6412
kathryn@theyatesnetwork.com 

Back to Top